Rapid disintegrating oral tablet for treatment of diabetes
JP2020180110A
Pharmaceutical composition containing drug conjugate of cmet monoclonal binder
WO2020203880A1
Compound, method and pharmaceutical composition for dux4 expression adjustment
TW202045184A
Medicament for prophylaxis or treatment of pulmonary fibrosis
WO2020138481A1
Crystal of pyrophosphoric acid compound
WO2020100826A1
Crosslinked artificial nucleic acid alna
WO2020091036A1
Edaravone suspension for oral administration
WO2020080354A1
Electroencephalogram analysis apparatus, electroencephalogram analysis system, and electroencephalogram analysis program
AU2019353367A1
Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor
WO2020054871A1
Human anti-il-33 monoclonal-antibody-containing pharmaceutical composition
CA3103648A1
Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
KR20210032412A
Peripheral nerve disorder, peripheral nerve disorder, or a method of preventing or treating pain due to a disease recognized as a stellate cell disorder
TW202019946A
Amide compounds having an inducing action of bet protein decomposition and pharmaceutical use thereof
JP2020190766A
Information processing device, information processing method and program
JP2020186182A
Proteolysis targeting compound
KR20200138288A
Drug conjugates of cMET monoclonal binding agents, and uses thereof
WO2020181354A1
Endogenous plant expression enhancer
JP2019151626A
Pharmaceutical composition
SG11202005383RA
Compositions and methods for treating or preventing vasomotor symptoms
TW202021587A
Gastro-resistant controlled release oral dosage forms
